ROSEN, NATIONAL TRIAL COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS

Core Viewpoint - The article discusses a class action lawsuit against Marinus Pharmaceuticals, Inc. for allegedly making materially false and misleading statements regarding its business operations and clinical trials, particularly the RAISE trial and its implications for the RAISE II trial [6]. Group 1: Lawsuit Details - The lawsuit claims that defendants understated the risk of failing to meet early-stopping criteria in the RAISE trial and did not disclose that such failure could lead to stopping the separate Phase 3 RAISE II trial [6]. - As a result of these alleged misstatements, investors suffered damages when the true details became public [6]. Group 2: Class Action Participation - Investors who purchased Marinus securities during the Class Period (March 17, 2021, to May 7, 2024) may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must be appointed by August 5, 2024, to represent other class members in directing the litigation [9][7]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].